论文部分内容阅读
目的:通过检测膀胱移行细胞癌(BTCC)中E-Selectin、E-Selectin mRNA的表达结果,探讨其表达与肿瘤分级、分期的关系,并初步探讨其临床意义。方法:以免疫组化SABC法及原位杂交法分别检测32例膀胱移行细胞癌中E-Selectin、E-Selectin mRNA的表达,分析其与肿瘤分期、分级的关系。结果:32例膀胱移行细胞癌组织中23例E-Selectin mRNA的表达阳性,占71.8％,9例表达阴性,占28.2％;20例E-Selectin表达阳性,占62.5％,12例表达阴性,占37.5％;其表达与肿瘤的分级无关(P>0.05),但与肿瘤的临床分期明显相关(P<0.05);11例复发的BTCC患者中,11例E-Selectin mRNA表达阳性,10例E-Selectin表达阳性,其表达与肿瘤的复发显著相关。结论:在膀胱移行细胞癌中,E-Selectin及E-Selectin mRNA的表达明显上调,可能促进了膀胱移行细胞癌的血源性转移,且其表达与肿瘤的分期及复发有明显关系,可能成为判断膀胱移行细胞癌预后的一项重要指标。
Objective: To investigate the expression of E-Selectin and E-Selectin mRNA in transitional cell carcinoma of the bladder (BTCC), and to explore the relationship between the expression of E-Selectin and tumor grade and staging, and to explore its clinical significance. Methods: The expressions of E-Selectin and E-Selectin mRNA in 32 cases of bladder transitional cell carcinoma were detected by immunohistochemical SABC method and in situ hybridization respectively. The relationship between E-Selectin and E-Selectin mRNA was analyzed by staging and grading. Results: The positive expression of E-Selectin mRNA was detected in 23 cases of bladder transitional cell carcinoma (71.8%), negative in 9 cases (28.2%), E-Selectin expression in 20 cases (62.5%), negative expression in 12 cases (P <0.05). The positive expression of E-Selectin mRNA in 11 BTCC patients with recurrence was positive in 10 cases (P <0.05), but not in the grade of tumor (P> 0.05) E-Selectin expression was positive, the expression was significantly associated with tumor recurrence. Conclusion: The expression of E-Selectin and E-Selectin mRNA in transitional cell carcinoma of urinary bladder obviously increases, which may promote the hematogenous metastasis of transitional cell carcinoma of the bladder. The expression of E-Selectin and E-Selectin mRNA may be related to the staging and recurrence of bladder cancer. To determine the prognosis of bladder transitional cell carcinoma is an important indicator.